

CHANGING PATIENT OUTCOMES in **ATTR Amyloidosis**

MONDAY, MARCH 26, 2018 | 07:00 - 08:30

Goho & Josai | Floor 2F | KKR Hotel Kumamoto

Breakfast will be served from 06:30

OBJECTIVES

- To raise awareness of the latest data and expert recommendations surrounding controversies in the diagnosis, characterization, and management of ATTR amyloidosis
- To provide information on how to translate treatment advancements into clinical practice



MODERATOR: MORIE A. GERTZ, MD, MACP

Chair, Internal Medicine

Department of Internal Medicine, Division of Hematology

Bone Marrow Transplant Program

Mayo Clinic

Rochester, MN, USA

07:00 - 07:40

Early Diagnosis of ATTR Amyloidosis

- Isabelle Lousada, President & CEO, Amyloidosis Research Consortium
- Yohei Misumi, Kumamoto University, Japan
- Claudio Rapezzi, University of Bologna, Italy
- Hartmut Schmidt, University Hospital Münster, Germany

07:40 - 08:00

How Early Should You Target Patient Treatment?

- Teresa Coelho, Santo António Hospital, Porto, Portugal
- Mathew Maurer, Columbia University Medical Center, US

08:00 - 08:20

Translating Clinical Trial Endpoints

- P. James B. Dyck, Mayo Clinic, Rochester, US
- Márcia Waddington-Cruz, Federal University of Rio, Brazil

08:20 - 08:30

Open Q&A Session

This symposium is supported and organised by Ionis Pharmaceuticals

